1 |
Hirsch IH (2000). Integrative urology: a spectrum of complementary and alternative therapy. Urology 56:185-189
DOI
ScienceOn
|
2 |
Lee S, Min HG, Choi SH, Kim YJ, Oh SW, Park Y & Kim SS (2006). Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 14:172-179
DOI
|
3 |
Mehrabi S, Shirazi HG, Rastim M & Bayat B (2005). Analysis of serum prostate-specific antigen levels in men aged 40 years and older in yasuj, Iran. Urol J 2:189-192
|
4 |
Nickel JC (1998). Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol 81:383-387
DOI
|
5 |
Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW & Sun SZ (2008). Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food 11:207-214
DOI
ScienceOn
|
6 |
Tsai YS, Tong YC, Cheng JT, Lee CH, Yang FS & Lee HY (2006). Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats. Urol Int 77:269-274
DOI
ScienceOn
|
7 |
Ernst E (2002). The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 136:42-53
DOI
ScienceOn
|
8 |
Moon YT, Oh CH & Kim SC (1990). Clinical effect of Sitosterol ( ) on the treatment of benign prostatic hypertrophy. Korean Journal of Andrology 8:23-29
|
9 |
Pathak SK, Sharma RA & Mellon JK (2003). Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review). Int J Oncol 22:5-13
|
10 |
Carbin BE, Larsson B & Lindahl O (1990). Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 66:639-641
DOI
ScienceOn
|
11 |
Kondas J, Philipp V & Dioszeghy G (1996). Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 28:767-772
DOI
|
12 |
Weisser H, Tunn S, Behnke B & Krieg M (1996). Effects of the Sabal serrulata extract IDS 89 and its subfraction on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28:300-306
DOI
ScienceOn
|
13 |
Watson V, Ryan M, Brown CT, Barnett G, Ellis BW & Emberton M (2004). Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 172:2321-2325
DOI
ScienceOn
|
14 |
Barry MJ, Fowler FJ Jr., Bin L, Pitts JC 3rd, Harris CJ & Mulley AG Jr. (1997). The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 157:10-14
DOI
|
15 |
Braeckman J (1994). The extract of serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study. Curr Ther Res 55:776-785
DOI
ScienceOn
|
16 |
Willetts KE, Clements MS, Champion S, Ehsman S & Eden JA (2003). Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 92:267-270
DOI
ScienceOn
|
17 |
Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F & Wagner H (1992). Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung 42:547-551
|
18 |
Ortiz MV (1998). Alternative medicine: Incorporation into therapeutics topics. Am J Pharm Educ 62:208-212
|
19 |
Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA & Jones WA (2001). Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 33:217-225
DOI
ScienceOn
|
20 |
Di Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera M & Sciarra F (1992). Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 21:309-314
DOI
|
21 |
Lee DH, Yang WJ, Chung BH, Kim SI, Kim SJ & Kim HS (2005). A multicenter study of the detection rate for prostate cancer according to the serum prostate specific antigen level in Korean men. Korean Journal of Urology 46:433-437
|
22 |
Buck AC (2004). Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172:1792-1799
DOI
ScienceOn
|
23 |
Shoskes DA (2002). Phytotherapy in chronic prostatitis. Urology 60:35-37
DOI
ScienceOn
|
24 |
Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J & Mulrow C (1998). Saw Palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 280:1604-1609
DOI
ScienceOn
|
25 |
Bach D (2000). Placebo-controlled, long-term therapeutic study of a pumpkin seed extract product in patients with micturition complaints from benign prostatic hyperplasia. Urologe B 40:437-443
DOI
ScienceOn
|
26 |
Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A & Perrin P (1996). Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29:231-240
DOI
ScienceOn
|
27 |
Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R & Raynaud JP (2002). Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41:497-506
DOI
ScienceOn
|
28 |
Hisashi H, Masahiro N, Yoshifumi S, Kenichi T, Hiroshi K & Tsuneharu M (2005). Prevalence of lower urinary tract symptoms and seeking acupuncture treatment in men and women aged years or older: A community-based epidemiological study in Japan. Japanese Acupuncture and Moxibustion 1:27-35
|
29 |
Cristoni A, Di Pierro F & Bombardelli E (2000). Botanical derivatives for the prostate. Fitoterapia 71:S21-28
DOI
ScienceOn
|
30 |
Vickers A (2000). Recent advances: complementary medicine. BMJ 321:683-686
DOI
|
31 |
Melo EA, Bertero EB, Rios LA & Mattos D Jr. (2002). Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz J Urol 28:418-425
|
32 |
Wilt TJ, MacDonald R & Ishani A (1999). beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 83:976-983
|
33 |
Gossell-Williams M, Davis A & O'Connor N (2006). Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. J Med Food 9:284-286
DOI
ScienceOn
|
34 |
Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA & deKernion JB (2000). Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 163:1451-1456
DOI
ScienceOn
|
35 |
Singh YN, Devkota AK, Sneeden DC, Singh KK & Halaweish F (2007). Hepatotoxicity potential of saw palmetto (Serenoa repens) in rats. Phytomedicine 14:204-208
DOI
ScienceOn
|
36 |
Cho JS, Kim CI, Seong DH, Kim HS, Kim YS & Kim SJ (2005). Relationship between serum prostate specific antigen and prostate volume in men with benign prostatic hyperplasia from multicenter study. Korean Journal of Urology 46:792-798
|
37 |
Wilt TJ, Ishani A, Rutks I & MacDonald R (2000). Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459-472
DOI
ScienceOn
|